Elucidation of NF2's tumor supressive function
Elucidation of NF2's tumor supressive function
批准号:
7474691
负责人:
Chunling Yi
金额:
$5.04万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-08-01 至 2009-07-31
关键词:
Animal ModelBindingDataDevelopmentERM proteinGTP BindingGenesInborn Genetic DiseasesLeadMalignant NeoplasmsModalityNamesNeurofibromatosis 2Neurofibromin 2PhenotypePhosphotransferasesProteinsSchwann CellsSignal TransductionTestingTherapeuticTumor Suppressor ProteinsVIII cranial nerve TumorValidationezringene functionmoesinp21 activated kinaseradixin proteinresearch studystemtumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Neurofibromatosis type 2 (NF2) is an inherited disorder characterized by development of Schwann cell tumors of the eighth cranial nerve. The NF2 gene encodes a protein named merlin, which is highly related to the ERM proteins (moesin, ezrin and radixin). Merlin is phosphorylated by Paks, which bind to activated (GTP-bound) Rac/Cdc42 and function as their direct effectors. Recent data implicate that merlin negatively regulates Rac/cdc42 signaling by directly interacting with and inhibiting Paks. The proposed project is geared towards establishing whether the Pak-inhibitory function of merlin is also merlin's tumor suppressive function. Furthermore, cellular and animal models will be employed to test whether inhibiting Pak function can reverse the transformed and cancer phenotypes that arise from NF2 deficiency. Finally, experiments will be carried out to identify additional mechanisms that may contribute to NF2 tumor suppressor function. Taken together, these studies will lead to a better understanding of merlin's tumor suppressive function. The validation of Paks as potential targets for inhibition, stemming from these studies, will point directly at approaches for the development of therapeutics towards the treatment of neurofibromatosis type 2.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.bcp.2010.03.012
发表时间:
2010-09-01
期刊:
BIOCHEMICAL PHARMACOLOGY
影响因子:
5.8
作者:
[Yi, Chunling, Maksimoska, Jasna, Marmorstein, Ronen, Kissil, Joseph L.]
通讯作者:
Kissil, Joseph L.
Strategies to Disrupt Oncogenic Transcription in RCC Tumors
-
批准号:10445067
-
项目类别:
-
资助金额:$34.97万
-
财政年份:2021
-
负责人:Chunling Yi
-
依托单位:
Strategies to Disrupt Oncogenic Transcription in RCC Tumors
-
批准号:10654832
-
项目类别:
-
资助金额:$34.97万
-
财政年份:2021
-
负责人:Chunling Yi
-
依托单位:
Strategies to Disrupt Oncogenic Transcription in RCC Tumors
-
批准号:10290131
-
项目类别:
-
资助金额:$35.69万
-
财政年份:2021
-
负责人:Chunling Yi
-
依托单位:
An Inducible Model for Studying Cancer Stem Cells in PDAC
-
批准号:10178478
-
项目类别:
-
资助金额:$40.11万
-
财政年份:2021
-
负责人:Chunling Yi
-
依托单位:
The Yap-Tead transcriptional complex in Kras-induced Pancreatic Ductal Adenocarci
-
批准号:8889233
-
项目类别:
-
资助金额:$32.27万
-
财政年份:2014
-
负责人:Chunling Yi
-
依托单位:
Elucidation of NF2's tumor supressive function
-
批准号:7154469
-
项目类别:
-
资助金额:$4.6万
-
财政年份:2006
-
负责人:Chunling Yi
-
依托单位:
Elucidation of NF2's tumor supressive function
-
批准号:7275324
-
项目类别:
-
资助金额:$4.88万
-
财政年份:2006
-
负责人:Chunling Yi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: